{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/nappy-rash/prescribing-information/flucloxacillin/","result":{"pageContext":{"chapter":{"id":"3e0033c5-591d-5608-8277-0cb6706398f5","slug":"flucloxacillin","fullItemName":"Flucloxacillin","depth":2,"htmlHeader":"<!-- begin field 1cc1831e-39b3-463d-bb77-a918010e6cbe --><h2>Flucloxacillin</h2><!-- end field 1cc1831e-39b3-463d-bb77-a918010e6cbe -->","summary":"","htmlStringContent":"<!-- begin item 0eed5de6-5e91-43c6-a718-a918010e6c3f --><!-- end item 0eed5de6-5e91-43c6-a718-a918010e6c3f -->","topic":{"id":"fced145b-8234-5cd6-8495-21dd435fa09e","topicId":"bf5cc007-7a69-42da-9cce-026e01ec0830","topicName":"Nappy rash","slug":"nappy-rash","lastRevised":"Last revised in September 2020","chapters":[{"id":"6bd868d7-97dc-5abb-9dd7-5bd8d9a45b42","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"285ad030-4a43-587e-b95d-111b05082bd7","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"51cba348-0401-515c-b0cb-403accf300bb","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"3faf55b7-5b1b-55f9-87fa-6c77ae443435","slug":"changes","fullItemName":"Changes"},{"id":"5d2e0f7f-32f0-515c-acf8-f41a7793f377","slug":"update","fullItemName":"Update"}]},{"id":"6afe2031-7d04-5d34-8f93-9f76b0cee31f","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"df2b7ca6-faa1-5155-b6f8-e38e875710a9","slug":"goals","fullItemName":"Goals"},{"id":"c88d8b1e-a003-5fdb-8125-60256108c8fd","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"2381dd75-9264-51ce-923a-ffd47d06fb70","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"9148277c-7b69-5abd-96e6-6da6cdc0692c","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"e337d403-433f-5884-ad90-0dc4725b9e10","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"98137183-55d3-54da-8a82-f70edd211099","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"2308d842-41bc-5c6e-b14f-7a732380baae","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"25c232ac-1d36-5623-a083-670842228d71","slug":"definition","fullItemName":"Definition"},{"id":"d6bc684b-0cf9-51f4-880a-68386599241c","slug":"prevalence","fullItemName":"Prevalence"},{"id":"0baab6c3-f7e8-573b-96ee-4e51d9cb5330","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"8e6a2c35-a2df-5ed9-8430-1d28fa50879e","slug":"complications","fullItemName":"Complications"},{"id":"808d9af1-4926-59a3-80ef-e810780e9314","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"34a7e7aa-63d3-5df0-9b78-2d694441515e","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"0f83f809-aed6-51e2-990d-c63ccf224d4e","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"36a8ef6d-dd7b-5e24-88b6-2e0d2e428522","slug":"assessment","fullItemName":"Assessment"},{"id":"da38cadb-36b7-5e94-a4d2-1ac880a9fc14","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"512f5f04-323c-5417-9d49-118aaf08ef60","fullItemName":"Management","slug":"management","subChapters":[{"id":"e22f1fdc-9a01-51a6-9519-694c4dc68f3e","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"919d8121-c385-56c1-a44a-d1b60e0744d8","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"54149fa7-c48e-56d7-909c-d76fceaaa0b6","slug":"topical-imidazoles","fullItemName":"Topical imidazoles"},{"id":"3e0033c5-591d-5608-8277-0cb6706398f5","slug":"flucloxacillin","fullItemName":"Flucloxacillin"},{"id":"4a82e127-a2d6-5fae-9103-e83494a28d24","slug":"clarithromycin","fullItemName":"Clarithromycin"}]},{"id":"01431b56-1a68-53cb-9666-0bc883bec5ff","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"186815e3-961f-5ab5-b89d-b7d341d8851a","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"c9ab642f-9b46-54ff-a595-1e9168cbfdff","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"a12c552f-6d1a-5409-a5cf-dc1efba7bb2a","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"d9167d23-de60-534b-b0da-c093d3a37b23","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"33ede077-9ff7-58b7-981d-d4dd371561b0","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"db7928f1-0104-5ed1-8880-c59b9f060e6f","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"96311897-ae0a-5de9-a6a0-0cb5e181a4d3","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"919d8121-c385-56c1-a44a-d1b60e0744d8","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"ee5ab99e-e975-5962-bc2e-2b8792a7803a","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 584e2911-2101-4f6e-a19d-a918010e8e45 --><h3>Contraindications and cautions</h3><!-- end field 584e2911-2101-4f6e-a19d-a918010e8e45 -->","summary":"","htmlStringContent":"<!-- begin item 2fa4999a-7c6a-4b15-a33e-a918010e8ce5 --><!-- begin field cff3d272-710a-45ab-adc4-a918010e8e45 --><p><strong>Do not prescribe flucloxacillin to people with:</strong></p><ul><li>A <em>true </em>penicillin hypersensitivity — gastrointestinal adverse effects alone (such as nausea, vomiting, or diarrhoea) do <em>not </em>constitute an allergy to penicillin.</li><li>A history of penicillin-associated jaundice or hepatic dysfunction — flucloxacillin has rarely been associated with hepatitis and cholestatic jaundice. The onset of hepatic reactions may be delayed for several weeks (up to 2 months) after treatment with flucloxacillin has stopped. These reactions are not related to the dose or route of administration of flucloxacillin. Risk factors include treatment for more than two weeks and increasing age.</li></ul><p><strong>Prescribe flucloxacillin with caution to people with:</strong></p><ul><li>Hepatic dysfunction (not flucloxacillin-related) — especially if they are 50 years or over, or have a serious underlying disease.</li><li>Renal impairment — consider dose reduction or a reduction in dosing interval of flucloxacillin in severe renal failure (creatinine clearance less than 10mL/min) due to the risk of neurotoxicity.</li><li>Hypersensitivity to cephalosporins — there is some clinical and laboratory evidence of partial cross-allergenicity of the penicillins and cephalosporins, and people have been known to have severe reactions (including anaphylaxis) to both drugs.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/nappy-rash/references/\">ABPI, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/nappy-rash/references/\">BNF for Children, 2017</a>]</p><!-- end field cff3d272-710a-45ab-adc4-a918010e8e45 --><!-- end item 2fa4999a-7c6a-4b15-a33e-a918010e8ce5 -->","subChapters":[]},{"id":"29255942-6ee4-5262-96cc-3eee705b64c1","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field e5d31437-a59e-44a0-9f3b-a918010eaf59 --><h3>Adverse effects</h3><!-- end field e5d31437-a59e-44a0-9f3b-a918010eaf59 -->","summary":"","htmlStringContent":"<!-- begin item 5e5ff708-8c8a-4f18-af2b-a918010eaed6 --><!-- begin field 0c20e6bb-8997-4e47-b616-a918010eaf59 --><ul><li><strong>Common adverse effects of flucloxacillin include:</strong><ul><li>Gastrointestinal disturbances, such as diarrhoea, nausea, vomiting.</li><li>Skin rash.</li><li>Joint pains.</li><li>Serum sickness-like reaction.</li></ul></li><li><strong>Other adverse effects include:</strong><ul><li>Antibiotic-associated colitis. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diarrhoea-antibiotic-associated/\">Diarrhoea - antibiotic associated</a> for more information.</li><li>Cholestatic jaundice and hepatitis.</li><li>Cerebral irritation, central nervous system toxicity, encephalopathy.</li><li>Coagulation disorders.</li><li>Haemolytic anaemia, leukopenia, thrombocytopenia.</li><li>Interstitial nephritis.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/nappy-rash/references/\">ABPI, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/nappy-rash/references/\">BNF for Children, 2017</a>]</p><!-- end field 0c20e6bb-8997-4e47-b616-a918010eaf59 --><!-- end item 5e5ff708-8c8a-4f18-af2b-a918010eaed6 -->","subChapters":[]},{"id":"856292e8-a927-5690-b953-41664b945c44","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field fd42af02-4ea5-4e98-a238-a918010ecb2b --><h3>Drug interactions</h3><!-- end field fd42af02-4ea5-4e98-a238-a918010ecb2b -->","summary":"","htmlStringContent":"<!-- begin item 5f940f67-1406-47e6-927f-a918010eca62 --><!-- begin field 4ec8609b-2741-4f76-b003-a918010ecb2b --><p><strong>Possible drug interactions with flucloxacillin include:</strong></p><ul><li>Anticoagulants (such as warfarin) — monitor the person’s international normalised ratio (INR) during concurrent use and adjust the warfarin dose accordingly. Prolongation of prothrombin time has been reported in people taking penicillins and warfarin concurrently.</li><li>Methotrexate — there have been rare reports of reduced excretion of methotrexate and acute methotrexate toxicity with concurrent use. One recommended approach is to carry out twice-weekly platelet and white cell count for two weeks initially and measure methotrexate levels if toxicity is suspected.</li><li>Probenecid — probenecid reduces the excretion of penicillin antibiotics, and may raise their serum levels. This may be a beneficial adverse effect but consider any possible detrimental effects of raised levels of penicillin antibiotics.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/nappy-rash/references/\">ABPI, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/nappy-rash/references/\">BNF for Children, 2017</a>]</p><!-- end field 4ec8609b-2741-4f76-b003-a918010ecb2b --><!-- end item 5f940f67-1406-47e6-927f-a918010eca62 -->","subChapters":[]},{"id":"806466d5-3354-58cf-acfd-d1c3dd9da6c4","slug":"dosage-regimens","fullItemName":"Dosage regimens","depth":3,"htmlHeader":"<!-- begin field da1cbca4-f423-4d9a-8873-a918010eee40 --><h3>Dosage regimens</h3><!-- end field da1cbca4-f423-4d9a-8873-a918010eee40 -->","summary":"","htmlStringContent":"<!-- begin item a6ebddf6-dc03-4f5e-916f-a918010eedd0 --><!-- begin field e975ab70-b10b-4747-bd87-a918010eee40 --><ul><li>Oral flucloxacillin is available as 250 mg and 500 mg capsules, and 125 mg per 5 mL and 250 mg per 5 mL oral solution. It should be taken one hour before food or on an empty stomach.</li><li>The dosage regimens for oral flucloxacillin are:<ul><li>Children 2–9 years of age — 125 mg to 250 mg, four times a day for 7 days.</li><li>Children 1 month to 1 year of age — 62.5 mg to 125 mg, four times a day for 7 days.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/nappy-rash/references/\">BNF for Children, 2017</a>]</p><!-- end field e975ab70-b10b-4747-bd87-a918010eee40 --><!-- end item a6ebddf6-dc03-4f5e-916f-a918010eedd0 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}